JATT merger with Talawar Tx
Talawar Tx (United States)Pre-revenue: the filings show no meaningful actual revenue for the most recent reported period.
Announced 29 June 2026.
Talawar Therapeutics (Talawar Tx Inc.) is a preclinical-stage biotechnology company developing bispecific antibodies for immunology and inflammatory (I&I) diseases, with its lead program TALA-125 targeting atopic dermatitis. The company is the first spinout from Khanda Therapeutics, L.P., a London-based biotech builder that translates validated biological insights into drug-development companies. Khanda's discovery engine designed and optimized TALA-125, a novel anti-IL-13 × anti-IL-18 bispecific antibody that combines two clinically validated, complementary mechanisms in a single molecule, aiming to break through the efficacy ceiling that monotherapies have hit in atopic dermatitis. The company's broader pipeline includes two discovery-phase programs, TALA-307 and TALA-711, in additional immunology indications. Talawar is headquartered in Westfield, New Jersey, and its intellectual property extends beyond 2045.
The company is led by CEO Marc Schegerin, MD, MBA, who previously served as COO and CFO at Morphic Therapeutic (acquired by Eli Lilly) and as CFO and Head of Strategy at ArQule. CMO Fabio Nunes, MD, MMSc, is an internist and medical geneticist who most recently served as Vice President of Dermatology and Respiratory Clinical Development at Johnson & Johnson, overseeing global Phase 2 and Phase 3 programs. Praveen Tipirneni, MD, MBA, formerly CEO of Caldera Therapeutics and Morphic Therapeutic, has joined the board, and Dan Becker, MD, PhD, Managing Director of Access Biotechnology, serves as board chair. The company appears to be pre-revenue, with its lead asset still preclinical; clinical entry for TALA-125 is expected in the first quarter of 2027, with interim Phase 1 data anticipated in the fourth quarter of 2027 and a Phase 2b proof-of-concept readout targeted for the second half of 2028.
On June 29, 2026, Talawar announced a definitive business combination agreement with JATT II Acquisition Corp. (Nasdaq: JATT), a SPAC led by Someit Sidhu, CEO of Khanda Therapeutics. The transaction is expected to provide approximately $285 million in gross proceeds, comprising $60 million held in JATT II's trust account (assuming no redemptions) and an oversubscribed $225 million concurrent PIPE priced at $10.00 per share. The PIPE was led by founding investor Access Biotechnology and includes Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital, Farallon Capital Management, and other healthcare-focused investors. The implied pre-PIPE equity valuation is approximately $120 million. The combined company will operate as Talawar Therapeutics and trade on Nasdaq under the ticker "TLWR," with closing expected in the second half of 2026.
Talawar chose the SPAC route over a traditional IPO primarily for speed and certainty of funding. CEO Marc Schegerin emphasized that given the company's clinical timeline, with interim Phase 1 data expected in late 2027, it was critical to secure a well-funded path to those milestones without the timing and execution risk inherent in a conventional IPO process. The $285 million in anticipated proceeds is designed to fund TALA-125 through its Phase 2b proof-of-concept readout in 2028, providing a multi-year development runway. The SPAC structure also allows Talawar to present its clinical thesis and development plan more directly to investors, though the deal carries the usual risks of shareholder redemptions potentially reducing the trust cash available at closing. The company's entry into the public markets comes amid significant competitive activity in atopic dermatitis, including AbbVie's $10.9 billion acquisition of Apogee Therapeutics, which Schegerin cited as validation of the value placed on differentiated, next-generation biologics in the space.
Structure & dilution
SEC-primary termsThe headline number ignores the shares that did not pay $10 — the founder promote, PIPE stock and warrants. This is the same deal with all equity claims counted.
Effective equity counts every claim on the post-close company at $10.00 — rollover, public shares, the founder promote and the PIPE. The headline counts only the target.
- PIPE
- ≈ $225M · unsourced
- Min-cash condition
- $125M
- Sponsor promote
- 22%
Led by founding investor Access Biotechnology, with Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital and Farallon Capital Management.more ▾less ▴
PIPE terms — instrument, coupon, conversion price and any reset floor — are not sourced for this deal. The size above is itself unsourced — a stored figure no filing we hold states — so neither the size nor the terms should be read as cited.
Lock-Up Period ” means the period beginning on the Closing Date and ending on the date that is one hundred eighty (180) days thereaftermore ▾less ▴
pursuant to which, among other things, the Sponsor shall agree to (a) vote in favor of this Agreement and the transactions contemplated hereby (including the Merger), (b) waive any adjustment to the conversion ratio set forth in the Governing Documents of JATT, any other anti-dilution or similar protections with respect to the JATT Shares (whether resulting from the transactions contemplated by the Investor Subscription Agreements or otherwise) and any redemption rights and (c) agree to surrender for no consideration, in connection with the Closing, 150,000 JATT Sharesmore ▾less ▴
Why headline and effective values differ is covered in headline vs effective deal value, in plain English.
The target: Talawar Therapeutics (Talawar Tx Inc.)
from 8-KThe business actually being bought — described from SEC primary filings, with projections labelled as projections.
Talawar Tx Inc. (d/b/a Talawar Therapeutics; Delaware corporation, press-release dateline New York, NY) is a PRECLINICAL, pre-revenue biotech - the first company formed to develop assets discovered by biotech company-builder Khanda Therapeutics, L.P. Its lead program TALA-125 is a novel anti-IL-13 x anti-IL-18 bispecific antibody for atopic dermatitis that pairs two clinically validated, largely orthogonal mechanisms to break the monotherapy 'efficacy ceiling'; it has NOT yet entered the clinic - first-in-human is expected 1Q2027, interim Phase 1 data 4Q2027, and post-deal cash is meant to fund it through a Phase 2b proof-of-concept readout in 2H2028. Two further discovery-phase programs, TALA-307 and TALA-711, target additional immunology indications. Leadership: CEO Marc Schegerin, MD, MBA (ex-COO/CFO Morphic Therapeutic, ex-CFO/Head of Strategy ArQule); CMO Fabio Nunes, MD, MMSc (ex-VP Dermatology & Respiratory Clinical Development, Johnson & Johnson); board chair Dan Becker, MD, PhD (Managing Director, Access Biotechnology - the founding investor); Praveen Tipirneni, MD (ex-CEO Morphic Therapeutic and Caldera Therapeutics) joins the board. The $225M oversubscribed PIPE at $10.00 (led by Access Biotechnology, with Bain Capital Life Sciences, Deep Track Capital, RA Capital, Janus Henderson, Vianti, Farallon) is nearly 2x the $120M pre-PIPE equity valuation of the company itself and almost 4x JATT II's $60M trust - the deal is effectively a PIPE-financed IPO of a preclinical asset with zero revenue and no clinical data.
The filings show no meaningful actual revenue for the most recent reported period.
Talawar Therapeutics (Talawar Tx Inc.) — every SPAC that has bid for it, and its listed peers
Expensive or cheap?
vs 4 listed peersA price only means something next to what the same kind of business costs on the stock market. This divides what the buyers are paying by what Talawar Therapeutics (Talawar Tx Inc.) actually sells, and sets the answer against its closest listed comparables — or says plainly when that cannot be done.
SpacBrain’s read on the price
No multiple can be computed
Talawar Therapeutics (Talawar Tx Inc.) has no meaningful revenue yet, so no multiple is computable — this is priced on a story, not on financials. The deal still values it at $422.2M.
The company reports no meaningful sales yet, so there is nothing to divide the price by.
Post-dilution equity (net debt unknown).
No meaningful revenue in the most recent reported period.
Not computable — the filings show no meaningful revenue for the most recent reported period.
$1 of their sales costs $22.87 on the open market. Median of 4 listed companies we judged a true comparable, which individually run from 4.84× to 43.92×. Their share prices are from 15 August 2026, not today.
What qualifies the figures above
- Struck on the post-dilution value of $422.2M, not the announced $120M — new shares handed to the sponsor, warrant holders and the PIPE are part of what public buyers are really paying.
- The target's cash and debt are not in the filings we have, so this is an equity value used as a stand-in for enterprise value.
- APGE, CTNM, CBIO, CGEN, EDSA, ZURA, SEPN, CLDX, TIL, IBIO, OABI, TCRT have no revenue to divide by, so they are shown but left out of the peer median.
The 16 listed companies it is measured against, and why
- APGEno revenue multiple
Apogee Therapeutics' lead APG777 is a clinical-stage anti-IL-13 antibody for atopic dermatitis - the most direct listed comp for TALA-125's target pathway, indication and stage.
- CTNMno revenue multiple
Direct comp: Biotechnology & Medical Research (NEC); small-cap ($427m); shares pipe, immunology, discovered, indications, preclinical, phase with the target's own description; forward EV/Sales 53.8x.
- REGN4.84× revenue
Regeneron's Dupixent (IL-4Ra) is the standard-of-care whose efficacy ceiling Talawar claims to shatter - the incumbent that defines the atopic dermatitis market.
- CBIOno revenue multiple
Operational comp: Pharmaceuticals (NEC); small-cap ($327m); shares bispecific, antibody, monotherapy, efficacy, clinically, biotechnology with the target's own description; forward EV/Sales 251.5x.
- ANAB7.28× revenue
AnaptysBio is a clinical-stage antibody company focused squarely on inflammation & immunology - comparable pre-commercial I&I antibody valuation anchor.
- CGENno revenue multiple
Operational comp: Biotechnology & Medical Research (NEC); micro-cap ($145m); shares preclinical, immunology, discovered, therapeutic, monotherapy, discovery with the target's own description; forward EV/Sales 9.2x.
- CNTB43.92× revenue
Connect Biopharma's rademikibart (anti-IL-4Ra) targets the same atopic dermatitis/inflammatory space at clinical stage with a small-cap valuation like Talawar's.
- EDSAno revenue multiple
Operational comp: Bio Therapeutic Drugs; micro-cap ($17m); shares dermatology, respiratory, biotech, dermatitis, anti, phase with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.
- NKTR38.46× revenue
Nektar's rezpegaldesleukin is in late-stage development for atopic dermatitis - another single-asset-driven I&I biologics story at comparable market value.
- ZURAno revenue multiple
Zura Bio develops bispecific/dual-pathway antibodies (tibulizumab) for immune-mediated diseases - the same two-pathways-one-molecule thesis at preclinical-to-early-clinical stage.
- SEPNno revenue multiple
Operational comp: Biotechnology & Medical Research (NEC); small-cap ($1.2bn); shares therapeutic, immunology, respiratory, inflammation, validated, biotechnology with the target's own description; forward EV/Sales 21.8x.
- CLDXno revenue multiple
Operational comp: Biotechnology & Medical Research (NEC); small-cap ($1.8bn); shares bispecific, therapeutics, atopic, dermatitis, antibody, antibodies with the target's own description; forward EV/Sales 1630.1x.
- TILno revenue multiple
Operational comp: Biotechnology & Medical Research (NEC); micro-cap ($75m); shares bispecific, antibodies, antibody, efficacy, anti, novel with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.
- IBIOno revenue multiple
Operational comp: Biotechnology & Medical Research (NEC); micro-cap ($15m); shares bispecific, anti, antibody, biotech, antibodies, pre with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.
- OABIno revenue multiple
Operational comp: Biotechnology & Medical Research (NEC); micro-cap ($267m); shares antibodies, bispecific, biotech, therapeutics, discovery, antibody with the target's own description; forward EV/Sales 14.9x.
- TCRTno revenue multiple
Operational comp: Bio Therapeutic Drugs; micro-cap ($7m); shares expected, therapeutics, pre, fund, clinical, capital with the target's own description; no forward EV/Sales published — counted as a peer, excluded from the median.
Which companies count as comparable is our judgement, written out above so you can disagree with it. The median is what these shares happened to trade at on the date given — not a price anyone is offering for this deal.
In plain English
No floor / floorlessthe cash guarantee is gone — the price is unprotected
A SPAC's downside protection is not the cash in trust; it is your right to demand that cash. Once the redemption window closes, the cash stays with the company and the share can trade anywhere.
Dilutionhow much of the company new shares take from you
Sponsor promote, PIPE shares, warrants and rights all issue stock that did not pay $10 for it. The headline deal value is before that; the effective value is after.
Pro-forma equitywhat the company is valued at once the deal closes
The combined company's equity value assuming the announced terms and the redemptions that have actually happened.
De-SPACthe day the SPAC becomes the real company
The shares stop being a claim on a pot of cash and start being equity in an operating business. Roughly 80% of recent de-SPACs traded below $10 within a year.
Outside datethe contractual long-stop for closing the deal
A deadline between the SPAC and its target, not between the SPAC and you. It confers no right to cash, which is exactly why it must never be counted as a redemption window.